Understand this story
Pathos AI Inc. announced the completion of a $237 million Series E funding round at a valuation of $3 billion. According to a report by SiliconANGLE, the round was led by Bristol Myers Squibb, with AstraZeneca, NEA, General Atlantic and others as existing investors. The company uses an AI platform called Foundry to analyze approximately 200 PB of oncology data, employing AI agents to screen candidate molecules and plan biomarker-driven clinical trials. The funds from this round will be used to advance the JSKN016 antibody-drug conjugate program and three other drug programs, one of which is an ER PROTAC drug being developed in collaboration with AstraZeneca; Pathos will also pay Tempus AI $55 million over five years to obtain licensed access to anonymized data from patients with neurological diseases. No further progress has been disclosed at this time.
AI-generated from public reports
Latest development · Report
AI pharmaceutical company Pathos AI completes $237 million financing at a $3 billion valuationDevelopments
1 confirmed developments
- Source:SiliconANGLE
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 24
SiliconANGLE
AI pharmaceutical company Pathos AI completes $237 million financing at a $3 billion valuation
Pathos AI announced the completion of $237 million in financing at a $3 billion valuation, led by Bristol Myers Squibb, with AstraZeneca, NEA and General Atlantic among existing investors. The company uses an AI platform called Foundry to analyze about 200 PB of oncology data, using AI agents to screen candidate molecules and plan biomarker-driven clinical trials. The funds will be used to advance the JSKN016 antibody-drug conjugate program and three other drug programs, one of which is an ER PROTAC drug developed in collaboration with AstraZeneca; Pathos will also pay Tempus AI $55 million over five years for licensed access to anonymized data from patients with neurological diseases.